Treatment-resistant Depression
📧 Sign up to get email alerts when something new happens for Treatment-resistant Depression.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: Psilocybin for Treatment-Resistant Depression [Phase 2]
Phase 2 clinical trial update for psilocybin in treatment-resistant depression; study completed.
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms [NA]
Clinical trial update on repetitive transcranial magnetic stimulation for adolescent treatment-resistant depression, including efficacy, pre…
-
FDA approval · 2023-05-01FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Par Health USA, LLC)
FDA announces a supplemental approval for a generic fixed-dose combination of olanzapine and fluoxetine by Par Health USA, LLC under ANDA 07…
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression [Phase 2]
Phase 2 trial update on the safety and efficacy of psilocybin in treatment-resistant depression; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Ketamine for Older Adults Pilot [Phase 4]
Pilot Phase 4 trial investigating ketamine for treatment resistant depression in older adults has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. [Phase 2]
Phase 2 trial update evaluating safety and efficacy of psilocybin for treatment-resistant depression in adults with bipolar II disorder.
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Open-Label Safety Study of AXS-05 in Subjects With Depression [Phase 3]
Open-label safety study of AXS-05 in subjects with depression completed; results posted in 2022.
-
CLINICAL_TRIALS withdrawal · 2022-08-10Clinical Trial Update: Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial [Phase 3]
Phase 3 trial of olanzapine augmentation for treatment-resistant depression was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-08-05Clinical Trial Update: ECT vs. Esketamine [Phase 3]
A Phase 3 clinical trial comparing electroconvulsive therapy (ECT) versus esketamine for treatment resistant depression and major depressive…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Mechanistic Evaluation of Response in TRD (MERIT) [Phase 2]
Phase 2 clinical trial evaluating mechanistic response in treatment resistant depression and major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: Optimizing Outcomes of Treatment-Resistant Depression in Older Adults [Phase 4]
Phase 4 trial update evaluating outcomes for treatment-resistant depression in older adults; results were posted in May 2022.
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: Psilocybin Versus Ketamine in Treatment-Resistant Depression [Phase 2]
Phase 2 trial update comparing psilocybin to ketamine in treatment-resistant depression (NCT05383313).
-
CLINICAL_TRIALS trial_result · 2022-04-21Clinical Trial Update: Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort [NA]
Clinical trial update for Stanford's OL Cohort of Accelerated Intelligent Neuromodulation Therapy in treatment-resistant depression has comp…
-
FDA approval · 2022-01-03FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
FDA approves Janssen's supplemental application for SPRAVATO (esketamine) to update its labeling for use in depression.
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial. [Phase 3]
Phase 3 randomized controlled trial evaluating simvastatin as an augmentation therapy for treatment resistant depression and major depressiv…
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients [Phase 2]
Phase 2 clinical trial evaluating AXS-05 for treatment-resistant depression in treatment-adherent patients.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: Psilocybin in Depression Resistant to Standard Treatments [Phase 2]
Phase 2 clinical trial update evaluating psilocybin for treatment-resistant depression.
-
CLINICAL_TRIALS trial_result · 2021-07-19Clinical Trial Update: Cannabidiol for Treatment Resistant Depression [Phase 4]
Phase 4 clinical trial evaluating cannabidiol for treatment resistant depression was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression [Phase 2]
Phase 2 proof-of-concept study evaluating MIJ821 for treatment-resistant depression has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD) [NA]
A completed clinical trial update for SAINT-TRD (Stanford Accelerated Intelligent Neuromodulation Therapy) investigating treatment-resistant…
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder [Phase 3]
Phase 3 trial assessing efficacy and safety of AXS-05 in treatment-resistant major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD [Phase 2]
Phase 2 trial update for REL-1017 in major depressive disorder shows safety, tolerability, pharmacokinetics, and symptom response with 7-day…
-
FDA approval · 2021-02-26FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for a generic olanzapine and fluoxetine product. The combination is indicated for depressive ep…
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: The UTHealth Ketamine Project [Phase 2]
Phase 2 trial update for the UTHealth Ketamine Project in treatment-resistant depression and major depressive disorder (terminated with resu…
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: Neuroimaging in Patients Undergoing TMS for Depression [NA]
Completed clinical trial evaluating neuroimaging in patients undergoing Transcranial Magnetic Stimulation for treatment-resistant depression…